HONG KONG, Apr 2, 2026 – (ACN Newswire) – Across the landscape of global biotech companies, the appointment of a senior executive often serves as a “barometer”—offering insights into a company’s pipeline potential and reflecting how industry veterans gauge the sector’s future.A clear signal of the company’s growth arrived in February 2026…
Read More
Mājas Uncategorized Dialogue with HighTide Therapeutics’ CMO Dr. Filip Surmont: Moving Beyond the “Blockbuster”...










